-
Mashup Score: 4Advances and Challenges in High-Risk CSPC: A Multidisciplinary Approach to Patient Management - Paul Sieber - 3 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Paul Sieber, MD, FACS, Keystone, Urology Specialists, Lancaster, PA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Chief Medical Officer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 42Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer - PubMed - 29 day(s) ago
PTEN LOF, identified with genomic testing, was associated with decreased survival and negative prognoses in patients with mCRPC.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Happy to share our work in @JCOPO_ASCO on real-world OS & Tx patterns by PTEN status in met #CSPC using @flatironhealth PTEN LOF ass w/ significantly ⬇️OS vs intact PTEN regardless of 1L Tx @RyonGraf @CleClinicMD @neerajaiims @montypal @PCF_Science https://t.co/s8E28bSUcu
-
-
Mashup Score: 4Advances and Challenges in High-Risk CSPC: A Multidisciplinary Approach to Patient Management - Paul Sieber - 1 month(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Paul Sieber, MD, FACS, Keystone, Urology Specialists, Lancaster, PA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Chief Medical Officer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma https://t.co/3aJQsloW0Q
-
-
Mashup Score: 3Advances and Challenges in High-Risk CSPC: A Multidisciplinary Approach to Patient Management - Paul Sieber - 2 month(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Paul Sieber, MD, FACS, Keystone, Urology Specialists, Lancaster, PA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Chief Medical Officer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma https://t.co/3aJQsloW0Q
-
-
Mashup Score: 0Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal - 9 month(s) ago
Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers….
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Beyond medical advancements: Addressing #financial and personal challenges in metastatic #CSPC treatment. @neerajaiims @huntsmancancer and @CaPsurvivorship @DanaFarber discuss the importance of addressing non-medical obstacles to #patientcare > https://t.co/FUpbRKytuf https://t.co/E5concY2oM
-
-
Mashup Score: 0Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal - 10 month(s) ago
Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Beyond medical advancements: Addressing #financial and personal challenges in metastatic #CSPC treatment. @neerajaiims @huntsmancancer and @CaPsurvivorship @DanaFarber discuss the importance of addressing non-medical obstacles to #patientcare > https://t.co/FUpbRKytuf https://t.co/AkGZ1Yurw2
-
-
Mashup Score: 0
ASTRO 2022 the impact of PSMA PET response on metastasis-free survival following stereotactic ablative radiation therapy among men with oligometastatic castration-sensitive prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PSMA PET response associates with MFS following stereotactic ablative radiation therapy in oligometastatic #CSPC. Presented by Philip Sutera, MD @HopkinsMedicine. #ASTRO22 coverage by @zklaassen_md @GACancerCenter > https://t.co/IshVlZUFBX @ASTRO_org https://t.co/RxAf16EWNe
-
-
Mashup Score: 0ARASENS Trial: Darolutamide-Containing Triplet Therapy for mCSPC - 2 year(s) ago
After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic #CSPC. #pcsm #mcspc @MayoClinic @MethodistHosp @orlandohealth https://t.co/llipcpWQNk
-
-
Mashup Score: 0Case 2: A 72-Year-Old Man With Metastatic CSPC - 2 year(s) ago
Key opinion leaders review the case of a 72-year-old man with metastatic CSPC and consider optimal treatment approaches in this setting.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Key opinion leaders review the case of a 72-year-old man with metastatic #CSPC and consider optimal treatment approaches in this setting. #pcsm @MayoClinic @MethodistHosp @orlandohealth https://t.co/IlwSVAjPU0
-
-
Mashup Score: 1Possible changes in the standard of care for prostate cancer - 3 year(s) ago
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer studies report at ESMO 2021
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO21: New data from PEACE-1 & STAMPEDE report significant OS improvement in pts (metastatic & non-metastatic) with castration-sensitive #prostatecancer receiving abiraterone upfront 👉https://t.co/XXvZizyoIt #pcsm #CSPC #visualabstract @DrChoueiri https://t.co/ok3OZnNQho
-
Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma https://t.co/3aJQsloW0Q